Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -30.75% is 55% above its 2-year average of -68.11%, near the high end of its 2-year range (-134.75%–-22.77%).
11.61% above its 12-month average of -34.79%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.89%.
RETURN ON ASSETS (ROA)
-30.75%
RETURN ON ASSETS (ROA) AVG TTM
-34.79%
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+11.61%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.07%
median of 561 covered companies
CURRENT VS SECTOR MEDIAN
-9.55%
vs the sector median at left
Carlsmed, Inc.
Market Cap
$411.99M
Return on Assets (ROA)
-30.75%
TTM Avg
-34.79%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$408.14M
Return on Assets (ROA)
-71.16%
TTM Avg
-43.23%
3Y Avg
-31.68%
5Y Avg
-18.72%
Market Cap
$410.91M
Return on Assets (ROA)
-41.33%
TTM Avg
-54.52%
3Y Avg
-54.52%
5Y Avg
-54.52%
Market Cap
$408.54M
Return on Assets (ROA)
-23.05%
TTM Avg
-30.00%
3Y Avg
-27.77%
5Y Avg
-27.77%
Market Cap
$392.24M
Return on Assets (ROA)
-41.58%
TTM Avg
-23.89%
3Y Avg
-13.16%
5Y Avg
-19.94%
Market Cap
$428.93M
Return on Assets (ROA)
-31.15%
TTM Avg
-77.61%
3Y Avg
-57.20%
5Y Avg
-46.24%
Market Cap
$431.90M
Return on Assets (ROA)
-35.10%
TTM Avg
-26.63%
3Y Avg
-37.28%
5Y Avg
-39.51%
Market Cap
$389.14M
Return on Assets (ROA)
-62.39%
TTM Avg
-45.13%
3Y Avg
-56.85%
5Y Avg
-56.85%
Market Cap
$441.36M
Return on Assets (ROA)
-0.01%
TTM Avg
-18.05%
3Y Avg
-43.07%
5Y Avg
-43.70%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Carlsmed, Inc. (CARL) | $411.99M | -30.75% | -34.79% | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $408.14M | -71.16% | -43.23% | -31.68% | -18.72% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $410.91M | -41.33% | -54.52% | -54.52% | -54.52% |
| Shoulder Innovations, Inc. (SI)vs › | $408.54M | -23.05% | -30.00% | -27.77% | -27.77% |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $392.24M | -41.58% | -23.89% | -13.16% | -19.94% |
| Editas Medicine, Inc. (EDIT)vs › | $428.93M | -31.15% | -77.61% | -57.20% | -46.24% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $431.90M | -35.10% | -26.63% | -37.28% | -39.51% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $389.14M | -62.39% | -45.13% | -56.85% | -56.85% |
| Assembly Biosciences, Inc. (ASMB)vs › | $441.36M | -0.01% | -18.05% | -43.07% | -43.70% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $378.75M | -69.44% | -48.37% | -55.05% | -50.20% |
ROA
-30.8%
ROE
-43.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -22.77% |
| 2024-12-31 | -46.81% |
| 2023-12-31 | -134.75% |
